Market Access Today’s Post

As of 2026, the European Pharmacopoeia will no longer include RPT. LumiMAT™ presents a cruelty-free alternative to the use of animal-based RPT. Not only does this method have greater reliability compared to the LAL assay, but it can also identify non-endotoxin pyrogens in addition to endotoxins. Learn more about LumiMAT™ Pyrogen Detection Kit: https://loom.ly/hznX6Mc #MAT #RPT #LALassay #endotoxin #pyrogen #pyrogentesting #endotoxintest #biopharmaceuticals #LumiMAT #EuropeanPharmacopoeia

FDA approves Livdelzi for Primary Biliary Cholangitis Aug 14, 2024 PBC is a rare, chronic, autoimmune disease of the bile ducts. It affects thousands globally, and primarily women. It can cause liver damage and possible liver failure if untreated. The disease currently has no cure. ALkaline Phosphatase (ALP) is a cholestatic biomarker and a predictor of risk for liver. Gilead’s Livdelzi (Seladelpar) is the First and Only Treatment to reduce severity of symptoms. Livdelzi, is an oral, peroxisome proliferator activated receptor (PPAR) delta agonist, or delpar. Livdelzi reduces levels of ALP significantly and help reduce pruritus - a common debilitating symptom of PBC. Thus it improves quality of life in people with PBC. #liverdisorder #pruritus #fdaapproval #researchanddevelopment #innovation #healthcare #lifesciences #QOL #biotechnology #pharmaceuticals #autoimmunedisorder

𝗗𝗢𝗦𝗜𝗨𝗥𝗔™, 𝗮 𝗻𝗲𝘄 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗗𝗣𝗗 𝗱𝗲𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴: 𝘂𝗿𝗮𝗰𝗶𝗹𝗲𝗺𝗶𝗮 𝗺𝗲𝗮𝘀𝘂𝗿𝗲𝗺𝗲𝗻𝘁 𝗯𝘆 𝗟𝗖-𝗠𝗦/𝗠𝗦 𝗮𝘀 𝗮𝗻 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 🩸 Screening for DPD (dihydropyrimidine dehydrogenase) deficiency in patients needing fluoropyrimidine-based chemotherapy is becoming a strong recommendation – if not mandatory – by health authorities in Europe in order to reduce the risk of severe drug toxicities that these treatments can cause. Indirect phenotyping of DPD deficiency can be performed by measuring the level of uracil and dihydrouracil in plasma. To facilitate the detection of DPD deficiency, the DOSIURA™ reagent kit offers a turnkey analytical solution with all the needed reagents for the precise quantification of these compounds by LC-MS/MS. Read full article here 👉 https://lnkd.in/e9Tyzeie

𝗗𝗢𝗦𝗜𝗨𝗥𝗔™, 𝗮 𝗻𝗲𝘄 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗗𝗣𝗗 𝗱𝗲𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴: 𝘂𝗿𝗮𝗰𝗶𝗹𝗲𝗺𝗶𝗮 𝗺𝗲𝗮𝘀𝘂𝗿𝗲𝗺𝗲𝗻𝘁 𝗯𝘆 𝗟𝗖-𝗠𝗦/𝗠𝗦 𝗮𝘀 𝗮𝗻 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 🩸 Screening for DPD (dihydropyrimidine dehydrogenase) deficiency in patients needing fluoropyrimidine-based chemotherapy is becoming a strong recommendation – if not mandatory – by health authorities in Europe in order to reduce the risk of severe drug toxicities that these treatments can cause. Indirect phenotyping of DPD deficiency can be performed by measuring the level of uracil and dihydrouracil in plasma. To facilitate the detection of DPD deficiency, the DOSIURA™ reagent kit offers a turnkey analytical solution with all the needed reagents for the precise quantification of these compounds by LC-MS/MS. Read full article here: https://lnkd.in/eVBcAi4Q

#ACROHighlights [Featured Product] 🚀 ASGR1: Pioneering Hyperlipidemia Treatments 🚀 Hyperlipidemia is a major health concern today, linked to serious conditions like cardiovascular disease and fatty liver. Targeting ASGR1 has emerged as a critical strategy for managing blood lipid levels. Future treatments combining ASGR1 and PCSK9-targeted biologics with statins promise to boost lipid-lowering effects by both inhibiting cholesterol synthesis and promoting its excretion. 💡Explore our offerings: https://smpl.is/99iyz #Biotech #Hyperlipidemia #ASGR1 #CardiovascularHealth #LipidManagement #PharmaInnovation #PCSK9 #Statins #LDLR #Biologics

Cholesterol-lowering #statins already improve the lives of millions of people worldwide – and they could soon be helping fight gum disease, too.💡 > Researchers at the Medical University of South Carolina have built upon previous studies suggesting that people who take statins tend to show fewer signs of gum infection, or periodontitis. > They discovered that the common statin drug simvastatin suppressed the inflammatory response generated by macrophages – a type of white blood cell key to the body’s immune system. > If further studies using statins on animals with gum disease prove successful, the treatment could potentially become a safe new way to combat periodontitis in humans. 🔬 LGC Standards supports statins research and analysis with 100+ TRC #ResearchChemicals and 60+ high quality #pharmaceutical #ReferenceMaterials from Mikromol: https://okt.to/dHFORG #ScienceForASaferWorld

FDA approves 'Fabhalta' for kidney disorder Aug 8, 2024 primary immunoglobulin A nephropathy (IgAN) is a progressive, rare disease in which the immune system attacks the kidneys. It often causes glomerular inflammation and proteinuria. Approximately 25 people per million worldwide are newly diagnosed with IgAN each year. Each person's disease journey is unique as IgAN progresses differently and treatment responses vary as well. Novartis' Fabhalta - Iptacopan is an oral, first-in-class complement inhibitor for the reduction of proteinuria. Fabhalta was approved by FDA in Dec 2023 for paroxysmal nocturnal hemoglobinuria (PNH). #researchanddevelopment #innovation #nephropathy #kidneydisorder #healthcare #lifesciences #biotechnology #pharmaceuticals #fdaapproval #rarediseases

FDA approves 'Fabhalta' for kidney disorder Aug 8, 2024 primary immunoglobulin A nephropathy (IgAN) is a progressive, rare disease in which the immune system attacks the kidneys. It often causes glomerular inflammation and proteinuria. Approximately 25 people per million worldwide are newly diagnosed with IgAN each year. Each person's disease journey is unique as IgAN progresses differently and treatment responses vary as well. Novartis' Fabhalta - Iptacopan is an oral, first-in-class complement inhibitor for the reduction of proteinuria. Fabhalta was approved by FDA in Dec 2023 for paroxysmal nocturnal hemoglobinuria (PNH). #researchanddevelopment #innovation #nephropathy #kidneydisorder #healthcare #lifesciences #biotechnology #pharmaceuticals #fdaapproval #rarediseases

Cholesterol-lowering #statins already improve the lives of millions of people worldwide – and they could soon be helping fight gum disease, too.💡 > Researchers at the Medical University of South Carolina have built upon previous studies suggesting that people who take statins tend to show fewer signs of gum infection, or periodontitis. > They discovered that the common statin drug simvastatin suppressed the inflammatory response generated by macrophages – a type of white blood cell key to the body’s immune system. > If further studies using statins on animals with gum disease prove successful, the treatment could potentially become a safe new way to combat periodontitis in humans. 🔬 LGC Standards supports statins research and analysis with 100+ TRC #ResearchChemicals and 60+ high quality #pharmaceutical #ReferenceMaterials from Mikromol: https://okt.to/wei9CR #ScienceForASaferWorld

💡 Researchers at the Medical University of South Carolina have built upon previous studies suggesting that people who take #statins tend to show fewer signs of gum infection, or periodontitis. > They have found that the common cholesterol-lowering drug, simvastatin, suppresses the inflammatory response generated by macrophages- a type of white blood cell key to the body’s immune system. > If further studies using statins on animals with gum disease prove successful, it could lead to a safe new way to fight periodontitis in humans. 🔬 In support of statins research and analysis, LGC Standards offers 100+ TRC #ResearchChemicals and 60+ high-quality #pharmaceutical #ReferenceMaterials from Mikromol. You can find them at https://okt.to/2W43Jz #ScienceForASaferWorld